NeurologyLive - Clinical Neurology News and Neurology Expert Insights articleshttps://www.neurologylive.com/newsNeurologyLive - Clinical Neurology News and Neurology Expert Insights articles© 2026 MJH Life Sciences™ and NeurologyLive - Clinical Neurology News and Neurology Expert Insights. All rights reserved.Sat, 13 Jun 2026 00:57:27 +00005en-us14447https://www.neurologylive.com/newshttps://www.neurologylive.com/logo.webphttps://www.neurologylive.com/view/phase-4-study-evaluates-direct-ivig-to-efgartigimod-transition-cidp-without-disease-worsening-requirementhttps://www.neurologylive.com/view/phase-4-study-evaluates-direct-ivig-to-efgartigimod-transition-cidp-without-disease-worsening-requirement<![CDATA[A phase 4 trial underway in the U.S. is examining whether patients with CIDP on stable IVIg can transition to efgartigimod PH20 SC within one week of their last infusion, without requiring documented disease worsening first.]]>Fri, 12 Jun 2026 21:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurologylive-friday-5-june-12-2026https://www.neurologylive.com/view/neurologylive-friday-5-june-12-2026<![CDATA[Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 12, 2026. ]]>Fri, 12 Jun 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/pariceract-fails-meet-primary-end-point-phase-2b-activate-trial-gba1-associated-pdhttps://www.neurologylive.com/view/pariceract-fails-meet-primary-end-point-phase-2b-activate-trial-gba1-associated-pd<![CDATA[Pariceract missed meeting the primary and key secondary efficacy end points in the phase 2b ACTIVATE trial, leading to the discontinuation of its development for GBA1-associated Parkinson disease.]]>Fri, 12 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/3-year-enlighten-analysis-links-lower-neurofilament-light-chain-levels-to-improved-cognition-early-ms-john-delucahttps://www.neurologylive.com/view/3-year-enlighten-analysis-links-lower-neurofilament-light-chain-levels-to-improved-cognition-early-ms-john-deluca<![CDATA[The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]]]>Fri, 12 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/key-takeaways-and-closing-thoughts-on-cidp-diagnosis-and-treatmenthttps://www.neurologylive.com/view/key-takeaways-and-closing-thoughts-on-cidp-diagnosis-and-treatment<![CDATA[Experts weigh CIDP care: IVIG limits, emerging therapies, early-yet-accurate diagnosis, objective response checks, and screening for paraproteins.]]>Fri, 12 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/safety-and-tolerability-of-fenfluramine-in-cdkl5-deficiency-disorderhttps://www.neurologylive.com/view/safety-and-tolerability-of-fenfluramine-in-cdkl5-deficiency-disorder<![CDATA[Epileptologist Sam Amin, MD, reviews the safety and tolerability findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, including treatment-emergent adverse events and the absence of major cardiovascular complications.]]>Fri, 12 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/episode-168-analyzing-phase-2-data-pacap-targeting-therapy-bocunebart-migrainehttps://www.neurologylive.com/view/episode-168-analyzing-phase-2-data-pacap-targeting-therapy-bocunebart-migraine<![CDATA[Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jessica Ailani, MD. [LISTEN TIME: 17 minutes]]]>Fri, 12 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/advancing-the-field-stem-cell-therapies-the-future-parkinson-disease-treatmenthttps://www.neurologylive.com/view/advancing-the-field-stem-cell-therapies-the-future-parkinson-disease-treatment<![CDATA[Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.]]>Thu, 11 Jun 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/extending-treatment-window-thrombolysis-acute-ischemic-stroke-fan-capriohttps://www.neurologylive.com/view/extending-treatment-window-thrombolysis-acute-ischemic-stroke-fan-caprio<![CDATA[The associate professor of neurology at Northwestern University Feinberg School of Medicine reviewed key aspects of the 2026 AHA/ASA stroke guidelines in acute ischemic stroke. [WATCH TIME: 5 minutes]]]>Thu, 11 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/clinical-preview-sleep-2026-key-themes-emerging-data-what-to-expecthttps://www.neurologylive.com/view/clinical-preview-sleep-2026-key-themes-emerging-data-what-to-expect<![CDATA[Romy Hoque, MD, Professor of Neurology at Emory University, previews the 2026 SLEEP Annual Meeting, highlighting key themes across neurodegeneration, hypersomnolence, sleep apnea, and the growing role of GLP-1 receptor agonists in sleep medicine.]]>Thu, 11 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/novel-migraine-targets-spotlighted-ahs-2026-amaal-starlinghttps://www.neurologylive.com/view/novel-migraine-targets-spotlighted-ahs-2026-amaal-starling<![CDATA[The associate professor of neurology at Mayo Clinic College of Medicine highlighted emerging migraine targets, repurposed therapies, and growing emphasis on patient-reported outcomes beyond monthly migraine days. [WATCH TIME: 3 minutes]]]>Thu, 11 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/disappointing-interim-analysis-forces-sanofi-discontinue-phase-3-mobilize-trial-riliprubarthttps://www.neurologylive.com/view/disappointing-interim-analysis-forces-sanofi-discontinue-phase-3-mobilize-trial-riliprubart<![CDATA[Sanofi stops the phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy because of insufficient likelihood of efficacy, with no safety signals reported.]]>Wed, 10 Jun 2026 21:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/cmsc-2026-highlights-ms-progression-biomarkers-comprehensive-care-carrie-hershhttps://www.neurologylive.com/view/cmsc-2026-highlights-ms-progression-biomarkers-comprehensive-care-carrie-hersh<![CDATA[The new president of Consortium of Multiple Sclerosis Centers (CMSC) discussed key themes in multiple sclerosis care presented at the 2026 CMSC Annual Meeting. [WATCH TIME: 11 minutes]]]>Wed, 10 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/fda-action-update-may-2026-approvals-priority-review-extension-reviewhttps://www.neurologylive.com/view/fda-action-update-may-2026-approvals-priority-review-extension-review<![CDATA[Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.]]>Wed, 10 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/seizure-burden-and-quality-of-life-in-grade-2-idh-mutant-gliomahttps://www.neurologylive.com/view/seizure-burden-and-quality-of-life-in-grade-2-idh-mutant-glioma<![CDATA[The discussion opens with a broad overview of seizure burden in grade 2 IDH-mutant glioma, highlighting how epilepsy affects quality of life, long-term disease management, and day-to-day functioning throughout the disease course.]]>Wed, 10 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurovoices-jinsy-andrews-prodromal-als-emerging-biomarkers-next-wave-targeted-therapieshttps://www.neurologylive.com/view/neurovoices-jinsy-andrews-prodromal-als-emerging-biomarkers-next-wave-targeted-therapies<![CDATA[Jinsy A. Andrews, MD, Director of the ALS Clinic and Director of Clinical Trials at NYU Langone Health, discussed the evolving ALS treatment landscape, including emerging gene-targeted therapies, and the next generation of disease biomarkers.]]>Wed, 10 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/current-emerging-strategies-managing-huntington-disease-symptoms-karen-andersonhttps://www.neurologylive.com/view/current-emerging-strategies-managing-huntington-disease-symptoms-karen-anderson<![CDATA[The professor of psychiatry and neurology reviewed approaches to treating chorea, cognitive impairment, apathy, irritability, and aggression in Huntington disease, while highlighting the promise of huntingtin-lowering therapies.]]>Tue, 09 Jun 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/understanding-mechanism-therapeutic-potential-vidofludimus-calcium-for-multiple-sclerosishttps://www.neurologylive.com/view/understanding-mechanism-therapeutic-potential-vidofludimus-calcium-for-multiple-sclerosis<![CDATA[Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.]]>Tue, 09 Jun 2026 21:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/improving-recognition-treatment-hyperkinetic-movement-disorders-zoltan-marihttps://www.neurologylive.com/view/improving-recognition-treatment-hyperkinetic-movement-disorders-zoltan-mari<![CDATA[At ATMRD 2026, the director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic discussed the importance of movement phenomenology and accurate diagnosis in guiding treatment decisions for patients with hyperkinetic disorders. [WATCH TIME: 7 minutes]]]>Tue, 09 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/improving-stability-with-advanced-therapies-in-parkinson-s-diseasehttps://www.neurologylive.com/view/improving-stability-with-advanced-therapies-in-parkinson-s-disease<![CDATA[A Parkinson’s patient reveals how off times, med trials and a continuous pump strain family life—and how advocacy brings stability.]]>Tue, 09 Jun 2026 12:05:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/differentiating-pathologic-features-ad-lewy-body-dementia-charbel-moussahttps://www.neurologylive.com/view/differentiating-pathologic-features-ad-lewy-body-dementia-charbel-moussa<![CDATA[At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]]]>Tue, 09 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/parkinson-s-disease-impact-on-daily-life-and-family-burdenhttps://www.neurologylive.com/view/parkinson-s-disease-impact-on-daily-life-and-family-burden<![CDATA[A Parkinson’s patient explains how a daily apomorphine pump smooths off time, cuts levodopa, and restores confidence, work, and social life.]]>Tue, 09 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/donanemab-shows-durable-amyloid-clearance-consistent-safety-early-start-patientshttps://www.neurologylive.com/view/donanemab-shows-durable-amyloid-clearance-consistent-safety-early-start-patients<![CDATA[Characterization of early-start TRAILBLAZER-ALZ 2 participants who required continued donanemab in the long-term extension suggests durable clinical benefit with fewer cumulative doses.]]>Tue, 09 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/masterclass-amtrd-highlights-real-world-applications-botulinum-toxin-movement-disorders-laxman-bahroo-mdhttps://www.neurologylive.com/view/masterclass-amtrd-highlights-real-world-applications-botulinum-toxin-movement-disorders-laxman-bahroo-md<![CDATA[The professor at MedStar Georgetown University Hospital spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]]]>Mon, 08 Jun 2026 22:46:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/subcutaneous-apomorphine-infusion-titration-reaches-optimization-without-antiemetics-real-world-pd-cohorthttps://www.neurologylive.com/view/subcutaneous-apomorphine-infusion-titration-reaches-optimization-without-antiemetics-real-world-pd-cohort<![CDATA[Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.]]>Mon, 08 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/ms-treatment-strategy-high-efficacy-therapy-vs-escalation-approachhttps://www.neurologylive.com/view/ms-treatment-strategy-high-efficacy-therapy-vs-escalation-approach<![CDATA[In this episode, panelists explore the question of "MS Treatment Strategy: High-Efficacy Therapy vs. Escalation Approach." Dr. Williams frames the central question: with earlier MS diagnoses now possible, how has treatment philosophy shifted? The traditional "start low, go slow" escalation model has given way to a high-efficacy-first approach for many clinicians.]]>Mon, 08 Jun 2026 14:20:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/evolving-ms-diagnostic-criteria-2024-mcdonald-criteria-and-what-s-newhttps://www.neurologylive.com/view/evolving-ms-diagnostic-criteria-2024-mcdonald-criteria-and-what-s-new<![CDATA[Welcome back to another Neurology Live Peer Exchange series. In this episode titled "Evolving MS Diagnostic Criteria: 2024 McDonald Criteria and What's New," moderator Dr. Mitzi Joi Williams discusses multiple sclerosis with Dr. Stephen Krieger.]]>Mon, 08 Jun 2026 14:15:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/cmsc-2026-latest-developments-in-ms-carehttps://www.neurologylive.com/view/cmsc-2026-latest-developments-in-ms-care<![CDATA[CMSC 2026 offerings underscore a holistic treatment philosophy that combines advanced pharmacology with lifestyle interventions, real-world data, and patient-centered research to improve long-term outcomes.]]>Mon, 08 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/advances-diagnosing-atypical-parkinsonisms-ataxias-david-shprecherhttps://www.neurologylive.com/view/advances-diagnosing-atypical-parkinsonisms-ataxias-david-shprecher<![CDATA[At ATMRD 2026, the director of Movement Disorders at Banner Sun Health Research Institute discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.]]>Mon, 08 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/this-week-on-neurologylive-june-8-2026https://www.neurologylive.com/view/this-week-on-neurologylive-june-8-2026<![CDATA[Here's some of what is coming soon to NeurologyLive® this week. ]]>Mon, 08 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles